BioArctic AB (LTS:0RV2) Total Equity: kr2,198 Mil (As of Mar. 2026)


LTS:0RV2 BioArctic AB LTS:0RV2
76 GF Score
Price kr330.30
GF Value kr476.78
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioArctic AB Total Equity?

BioArctic AB LTS:0RV2 -0.36% 76 Total Equity is kr2,198 Mil as of Mar. 2026. GuruFocus rates LTS:0RV2 with a GF Score™ of 76/100 and a GF Value™ of kr476.78 (Significantly Undervalued). The stock has 5 warning signs investors should review.

BioArctic AB's total equity for the quarter that ended in Mar. 2026 was kr2,198 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioArctic AB Total Equity Historical Data

* Premium members only.

The historical data trend for BioArctic AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB Total Equity Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 788.68 786.24 1,046.58 894.94 1,967.08

BioArctic AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,933.96 2,036.08 1,969.28 1,967.08 2,198.04
LTS:0RV2
76GF Score
BioArctic AB LTS:0RV2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioArctic AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2575.228-608.145
=1,967

BioArctic AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2679.252-481.21
=2,198

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr2,198 Mil mean?
BioArctic AB (LTS:0RV2) has a Total Equity of kr2,198 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for BioArctic AB and its competitors.
Is BioArctic AB's Total Equity too high?
BioArctic AB's current Total Equity is kr2,198 Mil. Overall, BioArctic AB has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Total Equity compare to VRTX and REGN?
BioArctic AB's Total Equity of kr2,198 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioArctic AB and its competitors. BioArctic AB's current Total Equity is kr2,198 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr476.78, compared to a current price of kr330.30 — trading 30.7% below its estimated fair value. The current Total Equity is kr2,198 Mil. BioArctic AB's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Total Equity is kr2,198 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (LTS:0RV2) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of kr330.30 is trading 30.7% below its estimated GF Value™ of kr476.78. GuruFocus considers BioArctic AB to be Significantly Undervalued.

Key valuation signals for LTS:0RV2:

  • Total Equity: kr2,198 Mil
  • GF Value™: kr476.78 vs. price of kr330.30 (30.7% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
76GF Score

Get the complete analysis for LTS:0RV2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr330.30
Price
kr476.78
GF Value